The GLP-1 anti-obesity drug class has matured and the disease areas in which its therapeutic potential is being investigated has expanded. This shift adds to research complexity and has implications for patient recruitment. Obesity trials will increasingly require an integrated approach to protocol design, recruitment and patient support.This playbook explores patient-centric strategies that drug developers can proactively adopt to stay ahead in the next era of GLP-1 research. Recruitment, engagement and support strategies that have already been proven successful will guide drug developers. Highlights include:The challenges unique to obesity research recruitment that impact eligibility. Why it’s critical to build an effective patient engagement framework that extends from trial design through execution. How delivering a best-practice patient engagement and patient support model can overcome the physical, emotional and logistical barriers to participation.
